Table 1: Drug Utilization Review Board member attendance at the Friday, July 26, 2019, meeting.

<table>
<thead>
<tr>
<th>MEMBER NAME</th>
<th>YES</th>
<th>NO</th>
<th>MEMBER NAME</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. James Barnes</td>
<td>X</td>
<td></td>
<td>Dr. Alejandro Kudisch</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Dr. Scott Blaszczyk</td>
<td>X</td>
<td></td>
<td>Dr. Mark D. Lacy</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Mr. Dennis Borel</td>
<td>X</td>
<td></td>
<td>Dr. Kim Pham</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Deborah Briggs</td>
<td>X</td>
<td></td>
<td>Dr. Jill Lester</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Oscar Brown</td>
<td>X</td>
<td></td>
<td>Dr. Thanh Hao Ngo</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Dr. Deeatra Craddock</td>
<td></td>
<td>X</td>
<td>Dr. Richard Noel</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Salil Deshpande</td>
<td></td>
<td>X</td>
<td>Dr. Joseph Vazhappilly</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Dr. Jennifer Fix</td>
<td></td>
<td></td>
<td>VACANT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Robert Hogue</td>
<td></td>
<td></td>
<td>VACANT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Summer Keener</td>
<td></td>
<td></td>
<td>VACANT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Left at 1:00 pm

Table 2: Drug Utilization Review Board state agency staff attendance at the Friday, July 26, 2019, meeting.

<table>
<thead>
<tr>
<th>STATE AGENCY STAFF NAME</th>
<th>YES</th>
<th>NO</th>
<th>STATE AGENCY STAFF NAME</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nahid Assadi, R.Ph</td>
<td>X</td>
<td></td>
<td>Kelani Condon, PharmD</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Aaliya Ahmad, PharmD</td>
<td>X</td>
<td></td>
<td>Gina Marie Muniz, CBCP</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Maribel O. Castoreno</td>
<td></td>
<td>X</td>
<td>Dr. Ryan Van Ramshorst</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Alish Valdez</td>
<td></td>
<td>X</td>
<td>Dr. Mitchel Abramsky</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Louisa Cervera</td>
<td></td>
<td>X</td>
<td>Cynthia Galindo</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Table 3: Drug Utilization Review Board contractor attendance at the Friday, July 26, 2019, meeting.

<table>
<thead>
<tr>
<th>CONTRACTOR NAME</th>
<th>YES</th>
<th>NO</th>
<th>CONTRACTOR NAME</th>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Andrews, Pharm.D. (Magellan Medicaid Administration)</td>
<td>X</td>
<td></td>
<td>Matthew Lennertz, Pharm.D. (Magellan Medicaid Administration)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Larry Dent Pharm.D., (Conduent)</td>
<td>X</td>
<td></td>
<td>Jennifer Seltzer, Pharm.D. (University of Texas College of Pharmacy)</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Christina Faulkner, Pharm.D. (Health Information Designs, LLC.)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Agenda Item 1: Call to Order
Dr. Robert Hogue called the meeting to order at 9:01 a.m. Dr. Hogue introduced and turned the floor over to Ms. Stephanie Gutierrez, HHSC, Advisory Committee Coordination Office. Ms. Gutierrez read meeting logistics and conducted roll call. Ms. Gutierrez noted there was a quorum.

Agenda Item 2: Approval of minutes from April 26, 2019
Ms. Gutierrez reminded members a copy of the DRAFT minutes was sent by email. Ms. Gutierrez asked if there were any necessary changes. Hearing none, Ms. Gutierrez requested a motion.

MOTION: Dr. Oscar Brown motioned to approve the April 26, 2019, minutes with Dr. James Barnes seconding the motion. A voice vote was taken, and the motion carried unanimously with no objections nor abstentions.

Agenda Item 3: Re-drawing of member terms
Ms. Gutierrez announced members will be drawing new terms. There are fifteen members who share the same term expiration of August 31, 2020. The Board will be drawing new terms to align with statute. There will be five members per each four-year staggered term.

1. Dr. James Barnes   1-year term expiring in August 31, 2020
2. Dr. Scott Blaszczzyk 1-year term expiring in August 31, 2020
3. Mr. Dennis Borel   1-year term expiring in August 31, 2020
4. Dr. Deborah Briggs 4-year term expiring August 31, 2023
5. Dr. Oscar Brown    3-year term expiring August 31, 2022
6. Dr. Deatra Craddock 3-year term expiring August 31, 2022
7. Dr. Salil Deshpande 4-year term expiring August 31, 2023
8. Dr. Jennifer Fix    3-year term expiring August 31, 2022
9. Dr. Robert Hogue    4-year term expiring August 31, 2023
10. Dr. Summer Keener  1-year term expiring in August 31, 2020
11. Dr. Alejandro Kudisch 3-year term expiring August 31, 2022
12. Dr. Mark Lacy      3-year term expiring August 31, 2022
13. Dr. Kim Pham       4-year term expiring August 31, 2023
14. Dr. Jill Lester    2-year term expiring August 31, 2021
15. Dr. Thanh Hao Ngo  2-year term expiring August 31, 2021
16. Dr. Richard Noel   4-year term expiring August 31, 2023
17. Dr. Joseph Vazhappilly 2-year term expiring August 31, 2021
18. PharmD (VACANT)   2-year term expiring August 31, 2021
19. Physician (VACANT) 2-year term expiring August 31, 2021
20. OB/GYN (VACANT)   1-year term expiring in August 31, 2020

Agenda Item 4: New Business
Dr. Hogue opened the floor to public comment on the drug classes on the therapeutic and clinical drug review for the Medicaid Preferred Drug List. Ms. Gutierrez read Public Comment Announcements to members of the Board and members of the audience.

Dr. Hogue reviewed the classes of drugs for public comment. The following individuals provided testimony to the Board and answered questions.
Members discussed:
- The demographic of Sickle Cell Disease being varied beyond African American descent.
- The need to have more treatment available in Medicaid/CHIP programs.
- The taste of sickle cell anemia treatments.
- Prescribed treatment versus over the counter treatment regarding adherence.

**Agenda Item 5: Public comment on new drugs to be reviewed for the Medicaid Preferred Drug List (PDL)**

Dr. Hogue opened the floor to public comment on the clinical drug reviews on new drugs to be reviewed for the Medicaid PDL.

There were no comments or testimonies given for the new drugs single reviews.

Dr. Hogue announced a 15-minute break at 9:54 a.m. to 10:10 a.m.

**Agenda Item 6: Therapeutic and clinical drug reviews and updates**

Dr. Hogue reconvened the meeting at 10:12 a.m.

Dr. Hogue turned the floor over to Dr. Matt Lennertz, Magellan Medicaid Administration, MMA. Dr. Lennertz reviewed points of the classes that have not been brought up by Public Comment or previous meetings.

**Agenda Item 7: Retrospective Drug Utilization Review (DUR)**

Dr. Hogue introduced and turned the floor over to Dr. Larry Dent, Board Certified Pharmacotherapy Specialist, Conduent, LLC. Dr. Dent referenced the PowerPoint and handout, *Texas DUR Board Proposed Retrospective DUR Intervention*.

**Agenda Item 7a: Report on recent retrospective DUR interventions**

Dr. Dent covered the report of recent interventions:
- Medication Adherence
- Mental Health Disorders
- Psychotropic Drugs in Adults

**Agenda Item 7b: Report on recent retrospective DUR intervention outcomes**

Dr. Dent reported on recent outcome reports:

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Representing</th>
<th>Recommendations</th>
<th>PDL Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexis Russell</td>
<td>PTC Therapeutics</td>
<td>Emflaza</td>
<td>Glucocorticoids, Oral</td>
</tr>
<tr>
<td>Samir Patel</td>
<td>Veloxis Pharmaceuticals</td>
<td>Envarsus XR</td>
<td>Immunosuppressives, Oral</td>
</tr>
<tr>
<td>Brian Sakurada</td>
<td>Aerie Pharmaceuticals</td>
<td>Rocklatan</td>
<td>Ophthalmic, Glaucoma Agents</td>
</tr>
<tr>
<td>Melissa Jones</td>
<td>Self</td>
<td>Open Access</td>
<td>Sickle Cell Anemia Treatments</td>
</tr>
<tr>
<td>Christina Heiner</td>
<td>Medunik</td>
<td>Siklos</td>
<td>Sickle Cell Anemia Treatments</td>
</tr>
<tr>
<td>Bethany Boyd</td>
<td>Pfizer, Inc</td>
<td>Nivestym</td>
<td>Colony Stimulating Factors</td>
</tr>
<tr>
<td>RoxAnn Dominguez</td>
<td>AbbVie</td>
<td>Skyrizi</td>
<td>Cytokine and CAM Antagonists</td>
</tr>
</tbody>
</table>
• Benzodiazepine Anxiolytics and Controlled Sedative Hypnotics
• Major Depressive Disorder Management

**Agenda Item 7c: Retrospective DUR Proposals**
Dr. Dent proceeded with retrospective DUR proposals:

- Attention Deficit Hyperactivity Disorder (ADHD) Medication Management

Members Discussed:
- Minimizing prescribers providing coverage within the same clinic
- Adults with ADHD and Narcolepsy are not targeted
- Binge eating disorders
- Interventions target providers and provide patient profiles to discuss with patients at visits

**MOTION:** Dr. Alejandro Kudisch made a motion to approve the Retrospective DUR proposals for ADHD Medication Management. Dr. James Barnes seconded the motion. A voice vote was taken, and the motion carried unanimously with no objections nor abstentions.

- Cough and Cold Medications

Members discussed:
- Updating the format of the letter to increase visual appeal for doctors
- Patient satisfaction scores tied to diagnoses
- Distributing posters/pamphlets to providers
- Funding guaifenesin products rather than other medications that are more effective

**MOTION:** Dr. Mark Lacy made a motion to approve the retrospective DUR Proposals for cough and cold medications. Dr. James Barnes seconded the motion. A voice vote was taken, and the motion carried unanimously with no objections nor abstentions.

- Influenza Prevention

Members discussed:
- The number of people who were treated for flu yet died
- Adding a disclaimer that protection of a vaccine is sustained for months but not the case for oral treatments
- Collecting data on who is prescribing the treatment
- The flu test being necessary
- Conducting a study to determine the number of flu testing in Texas
- How much treatment is for acute illness in consideration of optimal timing
- Communicating to patients and pharmacists that the retail pharmacy setting is now able to bill for flu vaccines
- Adding severe side effects of the medication that is treating influenza
- Evaluating newer technology that controls the utilization of antivirals.

**MOTION:** Dr. Mark Lacy made a motion to approve the retrospective DUR Proposals for influenza prevention as changed. Dr. James Barnes seconded the motion. A voice vote was taken, and the motion carried unanimously with no objections nor abstentions.
Agenda Item 8: Executive Work Session
Dr. Hogue announced the Board will go into closed session at 11:32 a.m. Dr. Hogue read the legislation granting the Board the ability to meet in executive session.

Agenda Item 9: Announcements of drugs recommended for the Medicaid PDL
Dr. Hogue reconvened the meeting from executive session at 1:15 p.m. Dr. Hogue turned the floor over to Dr. Lennertz. Dr. Lennertz reviewed, for the record, the proposed recommendations decided by the Board in executive session. Dr. Lennertz referenced the PowerPoint, *Texas Medicaid Drug Utilization Review Board July 26, 2019*.

Dr. Hogue requested a motion.

**MOTION**: Dr. Alejandro Kudisch motioned to approve and accept the proposed recommended drug list. Mr. Dennis Borel seconded. A voice vote was taken, and the motion carried unanimously with no objections nor abstentions.

Agenda Item 10: Prospective prior authorization proposals (clinical edits)
Dr. Hogue introduced and turned the floor over to Dr. Christina Faulkner, Pharm. D., Health Information Designs, LLC. Ms. Faulkner referenced the PowerPoint, *Texas HHSC DUR Board Meeting Prospective Prior Authorization Proposals*.

Agenda Item 10a. Cytokine and CAM antagonists – addition of Skyrizi (risankizumab-rzaa)
Dr. Faulkner presented clinical edits provided in the PowerPoint.

Members discussed:
- The frequency and cost

**MOTION**: Dr. Deborah Briggs made a motion to approve the prospective prior authorization proposals for Skyrizi. Dr. James Barnes seconded the motion. A voice vote was taken, and the motion carried unanimously with no objections nor abstentions.

Agenda Item 10b. GI Motility – Addition of Motegrity (prucalopride)
Dr. Faulkner presented clinical edits provided in the PowerPoint.

**MOTION**: Dr. Deborah Briggs made a motion to approve prior authorization proposals for Motegrity with a change of history being 180 days rather than 730 days. Dr. James Barnes seconded the motion. A voice vote was taken, and the motion carried unanimously with no objections nor abstentions.

Agenda Item 10c. Skeletal Muscle Relaxants - Update
Dr. Faulkner presented clinical edits provided in the PowerPoint.

Members discussed:
- The need to evaluate this drug further
- Registering as a pain clinic in Texas
- The current usage demographically
- Polling pain clinics regarding the limitation of these medications
- Gathering information from sources using these medications to determine impact of limitation

**MOTION**: Dr. Oscar Brown made a motion to table prior authorization proposals for Skeletal Muscle Relaxants. Dr. Jill Lester seconded the motion. A voice vote was taken, and the motion carried unanimously with no objections nor abstentions.
**ACTION ITEM**: Dr. Briggs will review diagnoses for spasticity to be excluded from the PA criteria and send her review to the program and Dr. Faulkner.

**Agenda Item 11: Retrospective drug use, criteria for outpatient use in Vendor Drug Program**

Dr. Hogue introduced and turned the floor over to Dr. Jennifer Seltzer, Pharm. D., University of Texas at Austin, College of Pharmacy. Dr. Seltzer the PowerPoint, *Texas Medicaid Vendor Drug Program Drug Utilization Review Board Meeting - Retrospective Drug Use Proposals*.

Dr. Seltzer presented on eight retrospective criteria sets updated for posting on the vendor drug webpage.

**MOTION**: Dr. James Barnes motioned to approve the retrospective drug use criteria for outpatient use in Vendor Drug Program (VDP) for all categories. Dr. Alejandro Kudisch seconded the motion. A voice vote was taken, and the motion carried unanimously with no objections nor abstentions.

**Agenda Item 12: Adjournment**

Dr. Hogue announced the next meeting will be on October 25, 2019 at 9:00 a.m. Dr. Hogue adjourned the meeting at 2:02 p.m.

The webcasting link is: [https://texashhsc.swagit.com/play/07262019-743](https://texashhsc.swagit.com/play/07262019-743)